Investigating inflammation's role in heart attacks
The Complex Role of the Inflammation Response Following an Acute Myocardial Infarction: the INFINITY (INFlammatIoN amI sTudY)
This study is trying to see if certain inflammation markers in the blood can help predict how well people recover after having a heart attack.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nicosia General Hospital Academic / other |
| Locations | 4 sites (Nicosia and 3 other locations) |
| Trial ID | NCT06065514 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the prognostic significance of specific cytokines and adipokines in patients who have experienced a myocardial infarction. By monitoring inflammatory markers at various time points after admission, the study seeks to understand their relationship with adverse cardiac outcomes and remodeling. A total of 120 patients over the age of 18 will be enrolled from multiple centers, with blood samples collected for analysis of key inflammatory markers. The findings could help identify potential prognostic indicators for better risk stratification in post-myocardial infarction care.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old who have been diagnosed with acute coronary syndrome and are referred for coronary angiography.
Not a fit: Patients with chronic renal failure, chronic liver disease, or active infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved risk assessment and management strategies for patients recovering from myocardial infarction.
How similar studies have performed: Previous studies have indicated the potential of inflammatory markers as prognostic tools in myocardial infarction, suggesting that this approach is promising but still requires further validation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. ACS (ST-ACS, NSTE-ACS, UA) referred for coronary angiography 2. Above 18 years old 3. Consent form obtained Exclusion Criteria: 1. Chronic Renal Failure (CRF) stage IV (e GFR \< 29 ml/min or creatinine \> 2 mg/dl) 2. Chronic Liver Disease (CLD) (ALT \> 2 times upper normal limit) 3. Chronic Inflammation and/or autoimmune diseases 4. Active Ca 5. Recent CVA (less than 1 month) 6. Recent (within 2 weeks) use of glucocorticoid drugs or immunosuppressive agents 7. Acute or chronic infection, major surgery, or trauma in the last month 8. Previous heart transplantation 9. Poor life expectancy 10. Cardiogenic shock 11. Cardiac arrest
Where this trial is running
Nicosia and 3 other locations
- Nicosia General Hospital — Nicosia, Cyprus (Recruiting)
- 1st University Department of Cardiology - AHEPA University Hospital — Thessaloniki, Greece (Not_yet_recruiting)
- 2nd University Department of Cardiology — Thessaloniki, Greece (Not_yet_recruiting)
- 3rd University Department of Cardiology — Thessaloniki, Greece (Not_yet_recruiting)
Study contacts
- Principal investigator: George Kassimis, MD, PhD — Second Department of Cardiology, Aristotle University of Thessaloniki
- Study coordinator: Andreas Mitsis, MD, MSc
- Email: andymits7@gmail.com
- Phone: +35796705559
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.